BPG is committed to discovery and dissemination of knowledge
Clinical Trials Study
Copyright: ©Author(s) 2026.
World J Exp Med. Mar 20, 2026; 16(1): 116584
Published online Mar 20, 2026. doi: 10.5493/wjem.v16.i1.116584
Table 3 Number of patients of difference between substance P concentration in nasal secretions and scores for each nasal symptom after administration of olopatadine
Substance P concentration, nasal symptoms
(+, +)
(+, -)
(-, +)
(-, -)
Sneezing0228
Rhinorrhea0228
Nasal blockage0219
Severity0228


Write to the Help Desk